19 February 2024 - FDA approval
The news that the company's Tagrisso product has been approved by the FDA for use in patients with lung cancer has prompted a spike in the share price today. Readers will recall that we only tipped shares in the company last Thursday at 9600p with the stock suitable for both long-term investors and those short-term traders who fancied a punt! We suggested that the latter should look to sell at around 11200p and so there is some way still to go to get to that level - but a share price gain of . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
